Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
AMRX Quote, Financials, Valuation and Earnings
Last price:
$12.48
Seasonality move
:
10.64%
Day range:
$12.28 - $12.67
52-week range:
$6.69 - $15.42
Dividend yield:
0%
P/E ratio:
55.37x
P/S ratio:
1.32x
P/B ratio:
5.62x
Volume:
1.4M
Avg. volume:
2.2M
1-year change:
52.75%
Market cap:
$3.9B
Revenue:
$3B
EPS (TTM):
$0.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$764M | $0.23 | 2.85% | 336.44% | $16.80 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$283.1M | $0.07 | 16.03% | -30.17% | $31.85 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$207.8M | -$0.33 | 16.41% | -1.6% | $38.60 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$952.5M | $1.10 | 3.04% | 4.71% | $88.87 |
|
CORT
Corcept Therapeutics, Inc.
|
$186.6M | -$0.14 | 18.7% | -71.78% | $67.40 |
|
PFE
Pfizer Inc.
|
$13.9B | $0.73 | 1.39% | 40.12% | $28.58 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$12.48 | $16.80 | $3.9B | 55.37x | $0.00 | 0% | 1.32x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$40.41 | $38.60 | $5.2B | 327.37x | $0.00 | 0% | 5.12x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$55.50 | $88.87 | $10.3B | 31.15x | $0.00 | 0% | 3.33x |
|
CORT
Corcept Therapeutics, Inc.
|
$42.49 | $67.40 | $4.6B | 52.54x | $0.00 | 0% | 6.77x |
|
PFE
Pfizer Inc.
|
$28.32 | $28.58 | $159.9B | 20.74x | $0.43 | 6.12% | 2.56x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
102.7% | 1.095 | 66.56% | 1.37x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
APLS
Apellis Pharmaceuticals, Inc.
|
56.17% | -6.433 | 14.91% | 2.58x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.343 | 5.63% | 3.25x |
|
CORT
Corcept Therapeutics, Inc.
|
0.93% | 1.347 | 0.17% | 2.60x |
|
PFE
Pfizer Inc.
|
43.81% | -0.072 | 49.24% | 0.70x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$297.2M | $114.5M | 4.94% | -587.3% | 14.06% | $84.1M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$170.2M | -$51.1M | 3.04% | 8.48% | -25.58% | -$14.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
CORT
Corcept Therapeutics, Inc.
|
$199.6M | $4.5M | 14.82% | 14.97% | 2.22% | $38.4M |
|
PFE
Pfizer Inc.
|
$11B | $3.8B | 5.07% | 8.69% | 21.58% | $4.5B |
Amneal Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AMRX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 6.09% compared to Amneal Pharmaceuticals, Inc.'s net margin of 96.33%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.36.5% $0.11 $2.7B ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About AMRX or ACAD?
Amneal Pharmaceuticals, Inc. has a consensus price target of $16.80, signalling upside risk potential of 34.62%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is AMRX or ACAD More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.316, which suggesting that the stock is 31.625% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock AMRX or ACAD?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or ACAD?
Amneal Pharmaceuticals, Inc. quarterly revenues are $814.3M, which are larger than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Amneal Pharmaceuticals, Inc.'s net income of $49.6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 55.37x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.32x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.32x 55.37x $814.3M $49.6M ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns AMRX or APLS?
Apellis Pharmaceuticals, Inc. has a net margin of 6.09% compared to Amneal Pharmaceuticals, Inc.'s net margin of -29.49%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Apellis Pharmaceuticals, Inc.'s return on equity of 8.48%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.36.5% $0.11 $2.7B APLSApellis Pharmaceuticals, Inc.85.13% -$0.47 $844.5M -
What do Analysts Say About AMRX or APLS?
Amneal Pharmaceuticals, Inc. has a consensus price target of $16.80, signalling upside risk potential of 34.62%. On the other hand Apellis Pharmaceuticals, Inc. has an analysts' consensus of $38.60 which suggests that it could fall by -4.48%. Given that Amneal Pharmaceuticals, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Amneal Pharmaceuticals, Inc. is more attractive than Apellis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 APLSApellis Pharmaceuticals, Inc.3 17 0 -
Is AMRX or APLS More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.316, which suggesting that the stock is 31.625% more volatile than S&P 500. In comparison Apellis Pharmaceuticals, Inc. has a beta of -0.189, suggesting its less volatile than the S&P 500 by 118.923%.
-
Which is a Better Dividend Stock AMRX or APLS?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Apellis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or APLS?
Amneal Pharmaceuticals, Inc. quarterly revenues are $814.3M, which are larger than Apellis Pharmaceuticals, Inc. quarterly revenues of $199.9M. Amneal Pharmaceuticals, Inc.'s net income of $49.6M is higher than Apellis Pharmaceuticals, Inc.'s net income of -$59M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 55.37x while Apellis Pharmaceuticals, Inc.'s PE ratio is 327.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.32x versus 5.12x for Apellis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.32x 55.37x $814.3M $49.6M APLSApellis Pharmaceuticals, Inc.5.12x 327.37x $199.9M -$59M
-
Which has Higher Returns AMRX or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of 6.09% compared to Amneal Pharmaceuticals, Inc.'s net margin of -5.2%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.36.5% $0.11 $2.7B BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About AMRX or BMRN?
Amneal Pharmaceuticals, Inc. has a consensus price target of $16.80, signalling upside risk potential of 34.62%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 60.13%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is AMRX or BMRN More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.316, which suggesting that the stock is 31.625% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.697%.
-
Which is a Better Dividend Stock AMRX or BMRN?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or BMRN?
Amneal Pharmaceuticals, Inc. quarterly revenues are $814.3M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Amneal Pharmaceuticals, Inc.'s net income of $49.6M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 55.37x while BioMarin Pharmaceutical, Inc.'s PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.32x versus 3.33x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.32x 55.37x $814.3M $49.6M BMRNBioMarin Pharmaceutical, Inc.3.33x 31.15x $895M -$46.6M
-
Which has Higher Returns AMRX or CORT?
Corcept Therapeutics, Inc. has a net margin of 6.09% compared to Amneal Pharmaceuticals, Inc.'s net margin of 11.83%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.36.5% $0.11 $2.7B CORTCorcept Therapeutics, Inc.98.74% $0.20 $653.9M -
What do Analysts Say About AMRX or CORT?
Amneal Pharmaceuticals, Inc. has a consensus price target of $16.80, signalling upside risk potential of 34.62%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $67.40 which suggests that it could grow by 58.63%. Given that Corcept Therapeutics, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 CORTCorcept Therapeutics, Inc.3 2 0 -
Is AMRX or CORT More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.316, which suggesting that the stock is 31.625% more volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.249, suggesting its less volatile than the S&P 500 by 75.089%.
-
Which is a Better Dividend Stock AMRX or CORT?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or CORT?
Amneal Pharmaceuticals, Inc. quarterly revenues are $814.3M, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Amneal Pharmaceuticals, Inc.'s net income of $49.6M is higher than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 55.37x while Corcept Therapeutics, Inc.'s PE ratio is 52.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.32x versus 6.77x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.32x 55.37x $814.3M $49.6M CORTCorcept Therapeutics, Inc.6.77x 52.54x $202.1M $23.9M
-
Which has Higher Returns AMRX or PFE?
Pfizer Inc. has a net margin of 6.09% compared to Amneal Pharmaceuticals, Inc.'s net margin of -9.34%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Pfizer Inc.'s return on equity of 8.69%.
Company Gross Margin Earnings Per Share Invested Capital AMRXAmneal Pharmaceuticals, Inc.36.5% $0.11 $2.7B PFEPfizer Inc.62.74% -$0.29 $154.2B -
What do Analysts Say About AMRX or PFE?
Amneal Pharmaceuticals, Inc. has a consensus price target of $16.80, signalling upside risk potential of 34.62%. On the other hand Pfizer Inc. has an analysts' consensus of $28.58 which suggests that it could grow by 0.92%. Given that Amneal Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Amneal Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMRXAmneal Pharmaceuticals, Inc.2 0 0 PFEPfizer Inc.8 15 1 -
Is AMRX or PFE More Risky?
Amneal Pharmaceuticals, Inc. has a beta of 1.316, which suggesting that the stock is 31.625% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.687%.
-
Which is a Better Dividend Stock AMRX or PFE?
Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.12% to investors and pays a quarterly dividend of $0.43 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.
-
Which has Better Financial Ratios AMRX or PFE?
Amneal Pharmaceuticals, Inc. quarterly revenues are $814.3M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Amneal Pharmaceuticals, Inc.'s net income of $49.6M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 55.37x while Pfizer Inc.'s PE ratio is 20.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.32x versus 2.56x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRXAmneal Pharmaceuticals, Inc.1.32x 55.37x $814.3M $49.6M PFEPfizer Inc.2.56x 20.74x $17.6B -$1.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
